Literature DB >> 24421475

Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer.

Matthew R Rutledge1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421475      PMCID： PMC3839449          DOI： 10.1310/hpj4804-274

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  25 in total

Review 1.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Authors:  F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.

Authors:  Jon D Herrington; Hai T Tran; Mark W Riggs
Journal:  Cancer Chemother Pharmacol       Date:  2005-08-25       Impact factor: 3.333

3.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

Authors:  Olga Geling; Hans-Georg Eichler
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 4.  Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Authors:  P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

5.  Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.

Authors:  U Yilmaz; G Polat; C Anar; H Halilcolar
Journal:  Indian J Cancer       Date:  2011 Oct-Dec       Impact factor: 1.224

6.  Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.

Authors:  H Okamoto; K Watanabe; Y Nishiwaki; K Mori; Y Kurita; I Hayashi; M Masutani; K Nakata; S Tsuchiya; H Isobe; N Saijo
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

7.  A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

Authors:  A Schmittel; L Fischer von Weikersthal; M Sebastian; P Martus; K Schulze; P Hortig; M Reeb; E Thiel; U Keilholz
Journal:  Ann Oncol       Date:  2006-01-19       Impact factor: 32.976

8.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors:  Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-07       Impact factor: 3.333

Review 9.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Authors:  P E Kintzel; R T Dorr
Journal:  Cancer Treat Rev       Date:  1995-01       Impact factor: 12.111

10.  Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.

Authors:  H Okamoto; K Watanabe; H Kunikane; A Yokoyama; S Kudoh; T Asakawa; T Shibata; H Kunitoh; T Tamura; N Saijo
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640
View more
  1 in total

1.  Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice.

Authors:  Seçkin Akgül; Bryan A Chan; Peter M Manders
Journal:  BMC Cancer       Date:  2022-07-30       Impact factor: 4.638
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.